Form 4: Haemonetics Corp CEO Christopher Simon Reports Stock Transactions

Christopher Simon, President & CEO of Haemonetics Corp, reports the disposal of shares to cover tax obligations and an acquisition through the employee stock purchase plan.

Summary

• Christopher Simon, the President & CEO of Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 15, 2024, 1,480 shares of common stock were disposed of to cover tax obligations at a price of $96.49.
• On May 16, 2024, 1,907 shares of common stock were disposed of to cover tax obligations at a price of $94.8.
• As of the report, Simon beneficially owns 254,448 shares of Haemonetics Corp.
• This number includes unvested RSUs and 289 shares acquired through the Employee Stock Purchase Plan on April 30, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. The CEO's participation in the Employee Stock Purchase Plan is a slightly positive signal.

Positives

• The CEO participates in the company's Employee Stock Purchase Plan, indicating confidence in the company's future.

Industry Context

Form 4 filings are routine and provide transparency into the trading activities of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) that vest over time.
• It is standard practice for executives to sell shares to cover tax obligations when these RSUs vest.
• The Employee Stock Purchase Plan is a common benefit offered by many companies, allowing employees to purchase company stock at a discounted rate.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The disposal of shares to cover tax obligations is a normal part of executive compensation and does not signal a lack of confidence in the company.

Key Dates